Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms

International Journal of Clinical Practice

Volumn 66, Issue 7, 2012, Pages 663-670

  Lee, K S ^a   Lee, Y S ^b   Kim, J C ^c   Seo, J T ^d   Lee, J Z ^e   Choo, M S ^f  

^a Sungkyunkwan University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Catholic Kwandong University   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN;

ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; COPING BEHAVIOR; DISEASE SEVERITY; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; FEMALE; GASTROINTESTINAL SYMPTOM; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; OPEN STUDY; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SELF REPORT; SYMPTOM; TREATMENT RESPONSE; XEROSTOMIA;

AGED; FEMALE; GOALS; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84862726200     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02951.x     Document Type: Article

References (29)

1. Lee KS, Lee YS,. Overactive bladder. Korean J Urol 2007; 48: 1191-208.
2. Herbison P, Hay-Smith J, Ellis G, Moore K,. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4. (Pubitemid 36461413)
3. Wright JG,. Evaluating the outcome of treatment. Shouldn't We be asking patients if they are better?. J Clin Epidemiol 2000; 53: 549-53. (Pubitemid 30394503)
4. Coyne KS, Tubaro A, Brubaker L, Bavendam T,. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68: 9-16. (Pubitemid 44189488)
5. Abrams P, Cardozo L, Fall M, et al., The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78. (Pubitemid 34195211)
6. Pleil AM, Coyne KS, Reese PR, et al., The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue - the BSW. Value Health 2005; 8 (Suppl 1): S25-34. (Pubitemid 43110283)
7. Coyne K, Revicki D, Hunt T, et al., Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74. (Pubitemid 34876130)
8. Coyne KS, Matza LS, Kopp Z, Abrams P,. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86. (Pubitemid 43673993)
9. Choo MS, Doo CK, Lee KS,. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 2008; 62: 191-6.
10. Hullfish KL, Bovbjerg VE, Gibson J, Steers WD,. Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol 2002; 187: 88-92. (Pubitemid 34800305)
11. Mahajan ST, Elkadry EA, Kenton KS, et al., Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194: 722-8. (Pubitemid 43333146)
12. Brubaker L, Shull B,. EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 171-3. (Pubitemid 40867384)
13. Srikrishna S, Robinson D, Cardozo L,. A longitudinal study of patient and surgeon goal achievement 2 years after surgery following pelvic floor dysfunction surgery. BJOG 2010; 117: 1504-11.
14. Brubaker L, Khullar V, Piault E, et al., Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J Pelvic Floor Dysfunct 2011; 22: 937-46.
15. Irwin DE, Milsom I, Hunskaar S, et al., Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14. discussion 14-5.
16. Stewart WF, Van Rooyen JB, Cundiff GW, et al., Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
17. Coyne KS, Sexton CC, Kopp ZS, et al., The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int 2011; 108: 1459-71.
18. Milsom I, Abrams P, Cardozo L, et al., How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6. (Pubitemid 34204313)
19. Kobelt G, Borgstrom F, Mattiasson A,. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003; 91: 190-5. (Pubitemid 36232833)
20. Holm-Larsen T, Weiss J, Langkilde L,. Economic burden of nocturia in the US adult population. J Urol 2010; 183 (Suppl): e1.
21. Corcos J, Casey R, Patrick A, et al., A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006; 97: 520-7.
22. Steers W, Corcos J, Foote J, Kralidis G,. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005; 95: 580-6. (Pubitemid 40311477)
23. Chapple CR, Martinez-Garcia R, Selvaggi L, et al., A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70. (Pubitemid 41188406)
24. Dmochowski RR, Peters KM, Morrow JD, et al., Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010; 75: 62-8.
25. Zinner NR, Mattiasson A, Stanton SL,. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807. (Pubitemid 34496674)
26. Chapple C, DuBeau C, Ebinger U, et al., Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23: 2347-58. (Pubitemid 350033436)
27. Wagg A, Wyndaele JJ, Sieber P,. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14-24.
28. Smith AL, Nissim HA, Le TX, et al., Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 2011; 77: 55-9.
29. Lee YS, Lee HN, Han JY, et al., Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study. J Urol 2011; 5: 1003-9.